Cargando…

Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer

OBJECTIVE: Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH(3)) and inter-alpha-trypsin inhibitor heavy chain H4 (ITIH(4)) are heavy chains of protein members belonging to the ITI family, which was associated with inflammation and carcinogenesis. However, the diagnostic value of ITIH(3) and ITIH(4...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xiao, Bai, Xiao-Yan, Li, Bowen, Li, Yanan, Xia, Kangkai, Wang, Miao, Li, Shujing, Wu, Huijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701429/
https://www.ncbi.nlm.nih.gov/pubmed/31481982
http://dx.doi.org/10.1155/2019/5069614
_version_ 1783445057350664192
author Jiang, Xiao
Bai, Xiao-Yan
Li, Bowen
Li, Yanan
Xia, Kangkai
Wang, Miao
Li, Shujing
Wu, Huijian
author_facet Jiang, Xiao
Bai, Xiao-Yan
Li, Bowen
Li, Yanan
Xia, Kangkai
Wang, Miao
Li, Shujing
Wu, Huijian
author_sort Jiang, Xiao
collection PubMed
description OBJECTIVE: Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH(3)) and inter-alpha-trypsin inhibitor heavy chain H4 (ITIH(4)) are heavy chains of protein members belonging to the ITI family, which was associated with inflammation and carcinogenesis. However, the diagnostic value of ITIH(3) and ITIH(4) in human colorectal cancer (CRC) remains unknown. METHODS: In total, 101 CRC patients and 156 healthy controls were enrolled. The concentrations of ITIH(3) and ITIH(4) proteins in plasma samples of participants were assessed using enzyme-linked immunosorbent assay. ITIH(3) and ITIH(4) expressions in human CRC tissues were additionally assessed via immunohistochemical staining (IHC). Receiver operating characteristic (ROC) was applied to estimate the diagnostic power of the two proteins, and the net reclassification improvement (NRI) was adopted to evaluate the incremental predictive ability of ITIH(3)/ITIH(4) when added to the tissue inhibitor of metalloproteinase-1 (TIMP-1). RESULTS: The plasma concentration of ITIH(3) in CRC patients (median: 4.370 μg/mL; range: 2.152–8.170 μg/mL) was significantly lower than that in healthy subjects (median: 4.715 μg/mL; range: 2.665–10.257 μg/mL; p < 0.001), while the ITIH(4) plasma level in subjects with CRC (median: 0.211 μg/mL; range: 0.099–0.592 μg/mL) was markedly increased relative to that in the control group (median: 0.134 μg/mL; range: 0.094–0.460 μg/mL, p < 0.001). Consistently, IHC score assessment showed a dramatic reduction in ITIH(3) expression and, conversely, upregulation of ITIH(4) in colorectal carcinoma specimens relative to adjacent normal colorectal tissues (p < 0.001 in both cases). The area under the curve (AUC) of the ROC for ITIH(4) (AUC = 0.801, 95% CI: 0.745–0.857) was higher than that for ITIH(3) (AUC = 0.638, 95% CI: 0.571–0.704, both p values < 0.001). The AUC of the ROC for combined ITIH(3) and ITIH(4) was even higher than that for carcinoembryonic antigen. NRI results showed that combining ITIH(3) and ITIH(4) with TIMP-1 significantly improved diagnostic accuracy (NRI = 17.12%, p = 0.002) for CRC patients compared to TIMP-1 alone. CONCLUSIONS: Circulating ITIH(3) and ITIH(4) levels are associated with carcinogenesis in CRC, supporting their potential diagnostic utility as surrogate biomarkers for colorectal cancer detection.
format Online
Article
Text
id pubmed-6701429
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-67014292019-09-03 Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer Jiang, Xiao Bai, Xiao-Yan Li, Bowen Li, Yanan Xia, Kangkai Wang, Miao Li, Shujing Wu, Huijian Dis Markers Research Article OBJECTIVE: Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH(3)) and inter-alpha-trypsin inhibitor heavy chain H4 (ITIH(4)) are heavy chains of protein members belonging to the ITI family, which was associated with inflammation and carcinogenesis. However, the diagnostic value of ITIH(3) and ITIH(4) in human colorectal cancer (CRC) remains unknown. METHODS: In total, 101 CRC patients and 156 healthy controls were enrolled. The concentrations of ITIH(3) and ITIH(4) proteins in plasma samples of participants were assessed using enzyme-linked immunosorbent assay. ITIH(3) and ITIH(4) expressions in human CRC tissues were additionally assessed via immunohistochemical staining (IHC). Receiver operating characteristic (ROC) was applied to estimate the diagnostic power of the two proteins, and the net reclassification improvement (NRI) was adopted to evaluate the incremental predictive ability of ITIH(3)/ITIH(4) when added to the tissue inhibitor of metalloproteinase-1 (TIMP-1). RESULTS: The plasma concentration of ITIH(3) in CRC patients (median: 4.370 μg/mL; range: 2.152–8.170 μg/mL) was significantly lower than that in healthy subjects (median: 4.715 μg/mL; range: 2.665–10.257 μg/mL; p < 0.001), while the ITIH(4) plasma level in subjects with CRC (median: 0.211 μg/mL; range: 0.099–0.592 μg/mL) was markedly increased relative to that in the control group (median: 0.134 μg/mL; range: 0.094–0.460 μg/mL, p < 0.001). Consistently, IHC score assessment showed a dramatic reduction in ITIH(3) expression and, conversely, upregulation of ITIH(4) in colorectal carcinoma specimens relative to adjacent normal colorectal tissues (p < 0.001 in both cases). The area under the curve (AUC) of the ROC for ITIH(4) (AUC = 0.801, 95% CI: 0.745–0.857) was higher than that for ITIH(3) (AUC = 0.638, 95% CI: 0.571–0.704, both p values < 0.001). The AUC of the ROC for combined ITIH(3) and ITIH(4) was even higher than that for carcinoembryonic antigen. NRI results showed that combining ITIH(3) and ITIH(4) with TIMP-1 significantly improved diagnostic accuracy (NRI = 17.12%, p = 0.002) for CRC patients compared to TIMP-1 alone. CONCLUSIONS: Circulating ITIH(3) and ITIH(4) levels are associated with carcinogenesis in CRC, supporting their potential diagnostic utility as surrogate biomarkers for colorectal cancer detection. Hindawi 2019-07-31 /pmc/articles/PMC6701429/ /pubmed/31481982 http://dx.doi.org/10.1155/2019/5069614 Text en Copyright © 2019 Xiao Jiang et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jiang, Xiao
Bai, Xiao-Yan
Li, Bowen
Li, Yanan
Xia, Kangkai
Wang, Miao
Li, Shujing
Wu, Huijian
Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
title Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
title_full Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
title_fullStr Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
title_full_unstemmed Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
title_short Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
title_sort plasma inter-alpha-trypsin inhibitor heavy chains h3 and h4 serve as novel diagnostic biomarkers in human colorectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701429/
https://www.ncbi.nlm.nih.gov/pubmed/31481982
http://dx.doi.org/10.1155/2019/5069614
work_keys_str_mv AT jiangxiao plasmainteralphatrypsininhibitorheavychainsh3andh4serveasnoveldiagnosticbiomarkersinhumancolorectalcancer
AT baixiaoyan plasmainteralphatrypsininhibitorheavychainsh3andh4serveasnoveldiagnosticbiomarkersinhumancolorectalcancer
AT libowen plasmainteralphatrypsininhibitorheavychainsh3andh4serveasnoveldiagnosticbiomarkersinhumancolorectalcancer
AT liyanan plasmainteralphatrypsininhibitorheavychainsh3andh4serveasnoveldiagnosticbiomarkersinhumancolorectalcancer
AT xiakangkai plasmainteralphatrypsininhibitorheavychainsh3andh4serveasnoveldiagnosticbiomarkersinhumancolorectalcancer
AT wangmiao plasmainteralphatrypsininhibitorheavychainsh3andh4serveasnoveldiagnosticbiomarkersinhumancolorectalcancer
AT lishujing plasmainteralphatrypsininhibitorheavychainsh3andh4serveasnoveldiagnosticbiomarkersinhumancolorectalcancer
AT wuhuijian plasmainteralphatrypsininhibitorheavychainsh3andh4serveasnoveldiagnosticbiomarkersinhumancolorectalcancer